2.1
Nivolumab–relatlimab (Opdualag, Bristol Myers Squibb) is indicated for 'the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older'.
2 Information about nivolumab–relatlimab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for nivolumab–relatlimab.
Price
2.3
Nivolumab–relatlimab costs £6,135 per 16 mg/ml vial (company submission).
2.4
The company has a commercial arrangement. This makes nivolumab–relatlimab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.